Nachrichten zur ASTRAZENECA DL-,25 SP.ADR Aktie

Merck (MRK) signs a new collaboration with a private drugmaker. AstraZeneca (AZN) gets approvals for expanded use of Imfinzi.…

This approval is based on late-stage study data, which shows that treatment with AstraZenecas (AZN) Imfinzi reduced the risk of…

NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat die Einstufung für Astrazeneca nach veröffentlichten Fachartikeln für die anstehende…

…

AstraZeneca Plc has become the first British company to be valued at more than £200 billion ($257 billion) after a…

Sonny Shergill, vice president of commercial digital health at AstraZeneca, highlights pharmas perspective on digital health investments and partnerships for…

Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments…

Todays Research Daily features new research reports on 16 major stocks, including AstraZeneca PLC (AZN), TotalEnergies SE (TTE) and ConocoPhillips…

AstraZenecas (AZN) key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga should drive sales. Its pipeline is huge, with several…

The winners of today might not compete in the lucrative new segment of tomorrow.…

1 August 2024 15:00 BST Transparency Directive Voting rights and capital The following notification is made in accordance with the UK Financial Conduct…

30 July 2024 07:00 BST AstraZeneca prices €1.4 billion bond offering AstraZeneca PLC (the Company) announces that, on 29 July 2024, its…

FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Astrazeneca auf "Hold" mit einem Kursziel von 11000 Pence…

29 July 2024 Fixed-duration Calquence plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival in 1st-line chronic lymphocytic leukaemia in AMPLIFY Phase III…

26 July 2024 FDA Advisory Committee reviewed Imfinzi for treatment of resectable non-small cell lung cancer based on AEGEAN Phase III trial results The…

AstraZeneca (AZN), Sanofi (SNY) and AbbVie (ABBV) announce second-quarter results. Merck (MRK) and Pfizers (PFE) phase III studies achieve primary…

…

AZN earnings call for the period ending June 30, 2024.…

2 and half trillion dollar Thursday. Thats the market cap of firms reporting on the busiest day for European earnings.…

AstraZeneca shares fall despite guidance raise as drugmaker warns on income…

CAMBRIDGE (dpa-AFX) - Der Pharmakonzern Astrazeneca hat nach dem zweiten Quartal seine Jahresprognose angehoben. Umsatz und Gewinn je Aktie…

The drop in AstraZeneca shares on Thursday was more a consequence of a wider market selloff than disappointed with the…

(Tippfehler berichtigt) CAMBRIDGE (dpa-AFX) - Der Pharmakonzern Astrazeneca hat nach einem starken zweiten Quartal seine Jahresprognose…

FTSE 100 drops 40 points to 8,114 Results out from AstraZeneca, Unilever, BAT, Lloyds ...and BT, Vodafone, Centrica, Airtel, Rentokil, Mitchells &...…

FTSE 100 drops 23 points to 8,130 Results out from AstraZeneca, Unilever, BAT, Lloyds ...and BT, Vodafone, Centrica, Airtel, Rentokil, Mitchells &...…

FTSE 100 climbs 1 points to 8,154 Results out from AstraZeneca, Unilever, BAT, Lloyds ...and BT, Vodafone, Centrica, Airtel, Rentokil, Mitchells &...…

FTSE 100 climbs 19 points to 8,173 Results out from AstraZeneca, Unilever, BAT, Lloyds ...and BT, Vodafone, Centrica, Airtel, Rentokil, Mitchells &...…

FTSE 100 climbs 3 points to 8,156 Results out from AstraZeneca, Unilever, BAT, Lloyds ...and BT, Vodafone, Centrica, Airtel, Rentokil, Mitchells &...…

FTSE 100 drops 70 points to 8,084 Results out from AstraZeneca, Unilever, BAT, Lloyds ...and BT, Vodafone, Centrica, Airtel, Rentokil, Mitchells &...…

FTSE 100 climbs 12 points to 8,166 Results out from AstraZeneca, Unilever, BAT, Lloyds ...and BT, Vodafone, Centrica, Airtel, Rentokil, Mitchells &...…

FTSE 100 drops 83 points to 8,070 Lloyds profits just beat forecasts Results out from AstraZeneca, BT, Vodafone, Unilever, BAT, Centrica,…

…

AstraZeneca lifts full-year outlook on upbeat demand for therapies…

AstraZeneca 25 July 2024 H1 and Q2 2024 results Strong underlying growth supports FY 2024 guidance upgrade, with both Total Revenue and Core…

© Foto: Sven Hoppe/dpa +++ dpa-Bildfunk Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im…

AstraZeneca (AZN) reports encouraging Q2 results. It also raises its financial guidance for the full year on the back of…

Is AstraZeneca set for another upgrade: ... read preview BT has had a tough first half according to one leading City firm,…

Eine wahren Datenflut erwartet uns am DonnerstagHeute stehen zahlreiche Unternehmensberichte an, darunter die Halbjahreszahlen von Audi, Hermes, Roche und AstraZeneca.…

Sales of AstraZenecas (AZN) key drugs like Imfinzi and Farxiga are expected to have been boosted by approvals in new…

…

AstraZenecas (AZN) key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga should drive sales. Its pipeline is huge with several…

15 July 2024 Acquisition of Amolyt Pharma completed AstraZeneca today announced the successful completion of theacquisition (https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-to-acquire-amolyt.html) of Amolyt Pharma, a clinical-stage biotechnology company focused…

LYON, France and CAMBRIDGE, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global, clinical-stage biopharmaceutical company…

Todays Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), AbbVie Inc. (ABBV) and…

SmartCella Holding AB (“SmartCella”) today announces a new share issue raising approximately EUR 50 million to accelerate growth and support…

The European Commission approves AstraZenecas (AZN) Tagrisso in combination with chemotherapy for first-line treatment of advanced EGFR-mutated NSCLC based on…

The CHMP recommends approval of AstraZenecas (AZN) Imfinzi plus Lynparza for treating primary advanced or recurrent endometrial cancer based on…

1 July 2024 15:00 BST Transparency Directive Voting rights and capital The following notification is made in accordance with the UK Financial Conduct…

…

The Global Food Allergy Treatment Market Size was Valued at USD 5.67 Billion in 2023 and the Worldwide Food Allergy…